The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Vertex Pharmaceuticals, Inc. shares valued at $461,198 were purchased by Biller Jonathan on Oct 02 ’24. At $461.66 per share, Biller Jonathan acquired 999 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, LEIDEN JEFFREY M sold 3,784 shares, netting a total of over 1,888,216 in proceeds. Following the sale of shares at $499.00 each, the insider now holds 9,994 shares.
Before that, Bhatia Sangeeta N. had sold 646 shares from its account. In a trade valued at $323,000, the Director traded Vertex Pharmaceuticals, Inc. shares for $500.00 each. Upon closing the transaction, the insider’s holdings decreased to 646 shares, worth approximately $2.05 million.
As published in a research note from Barclays on August 05, 2024, Vertex Pharmaceuticals, Inc. [VRTX] has been rated down from an Overweight to an Equal weight and the price target has been revised to $509 from $472. Analysts at Redburn Atlantic started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. As of April 11, 2024, Evercore ISI has increased its “an In-line” rating to a “an Outperform” for VRTX. Earlier on February 15, 2024, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for VRTX stock.
Analyzing VRTX Stock Performance
During the last five days, there has been a surge of approximately 0.08%. Over the course of the year, Vertex Pharmaceuticals, Inc. shares have jumped approximately 13.58%. Shares of the company reached a 52-week high of $510.64 on 08/01/24 and a 52-week low of $391.01 on 04/18/24. A 50-day SMA is recorded $478.22, while a 200-day SMA reached $444.32. Nevertheless, trading volume fell to 0.9 million shares from 1.13 million shares the previous day.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc. (VRTX)
According to the 24-hour chart, there is a support level at 459.10, which, if violated, would cause prices to drop to 456.07. In the upper region, resistance lies at 466.62. The next price resistance is at 471.11. RSI (Relative Strength Index) is 41.76 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.40, which suggests the price will decrease in the coming days. Percent R is at 82.19%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
